BRIGHT MINDS BIOSCIENCES Logo
CA10919W1086
A2QN4Y
DRUG

BRIGHT MINDS BIOSCIENCES

Forecast

The analysts' average price target is €100.77 (+419.97%). The median is €132.02 (+581.22%).

Buy
  5
Hold
  0
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Bright Minds Biosciences raises $175 million through placement of common shares

    Bright Minds Biosciences placed 1,945,000 common shares at $90.00 each, generating gross proceeds of $175.05 million. The syndicate banks were granted a 30-day overallotment option for up to 291,750 additional shares. The funds are intended to finance clinical trials (including the start of phase 1 for BMB-105), research and development of earlier programs, and general corporate purposes. » More on de.investing.com


  • Bright Minds Biosciences sets price for share offering at $90

    Bright Minds Biosciences has set the price for a public offering of 1,945,000 common shares at $90.00 per share and expects gross proceeds of about $175.05 million. The underwriters were granted a 30-day option to purchase up to 291,750 additional shares at the same price; closing is expected on January 9, 2026. The proceeds are intended to fund clinical trials for several drug candidates; the company has simultaneously ended its at-the-market program. Analysts mostly rate the stock as "Buy," and the share price and market capitalization have risen sharply after a strong rally. » More on de.investing.com


  • Bright Minds Biosciences plans public offering of $100 million

    Bright Minds Biosciences announced a public offering of common stock and pre-funded warrants totaling $100 million and granted the underwriters a 30-day option to purchase up to 15% of the offered common stock. Proceeds are intended to fund clinical trials for drugs targeting absence seizures, DEE and Prader‑Willi syndrome, as well as Phase 1 studies for BMB‑105, earlier-stage research and general corporate purposes. The offering is being made under an F-3 registration; Jefferies, TD Cowen, Piper Sandler and Cantor are serving as joint book-running managers. The company reports a strong balance sheet with more cash than debt and a current ratio of 36.1. » More on de.investing.com


  • Bright Minds Biosciences stock rises after positive phase‑2 data on BMB‑101

    The stock of Bright Minds Biosciences rose about 5% after positive topline results from the phase‑2 BREAKTHROUGH study of the selective 5‑HT2C agonist BMB‑101 in epilepsy‑associated disorders. In the 24‑patient study, median seizure frequency in absence epilepsy fell by 73.1% (p=0.012) and severe motor seizures in DEE patients by 63.3%. BMB‑101 also significantly improved REM sleep, was mostly well tolerated and showed no treatment‑related serious adverse events. Bright Minds is preparing global registration trials for DEE and absence epilepsy and plans a study in Prader‑Willi syndrome in Q1 2026. » More on de.investing.com


  • Bright Minds launches Prader‑Willi program and nominates BMB-105 as clinical candidate

    Bright Minds has launched a Prader‑Willi syndrome (PWS) program and nominated BMB-105 as a new clinical candidate. The company is starting the double‑blind, randomized phase‑2a NOVA study with BMB-101 to evaluate efficacy and safety in PWS patients and plans a parallel randomized, placebo‑controlled phase‑1 study of BMB-105 in healthy volunteers. BMB-101 has shown good tolerability so far in epilepsy studies, with top‑line data expected in January 2026; Bright Minds aims to accelerate time to market by roughly one year with BMB-105. » More on de.investing.com

Financials

In the last quarter, BRIGHT MINDS BIOSCIENCES had revenue of €0 and net profit of -€1.52M

(EUR) June 2026
YoY
Revenue 0 -
Gross profit -12.32K -
Net profit -1.52M 53.56%
EBITDA -7.22M 121.62%

Fundamentals

Metric Value
Market capitalization
€189.68M
Number of shares
9.86M
52-week high/low
€112.67 - €15.84
Dividends No
Beta
0.09
P/E ratio
-9.97
PEG ratio
0.13
P/B ratio
0.92
P/S ratio
0.00

Company profile

Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.

Name
BRIGHT MINDS BIOSCIENCES
CEO
Ian McDonald
Headquarters New York, ny
Canada
Website
Sector
Materials
Industry
Chemicals
IPO
03/22/2021
Employees 26

Ticker symbols

Exchange Symbol
NASDAQ
DRUG
đŸȘ

Parqet  uses cookies. Learn more